Suppr超能文献

健康与疾病中的铁调素-铁转运蛋白轴

Hepcidin-ferroportin axis in health and disease.

作者信息

Ginzburg Yelena Z

机构信息

Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

出版信息

Vitam Horm. 2019;110:17-45. doi: 10.1016/bs.vh.2019.01.002. Epub 2019 Feb 8.

Abstract

Hepcidin is central to regulation of iron metabolism. Its effect on a cellular level involves binding ferroportin, the main iron export protein, resulting in its internalization and degradation and leading to iron sequestration within ferroportin-expressing cells. Aberrantly increased hepcidin leads to systemic iron deficiency and/or iron restricted erythropoiesis. Furthermore, insufficiently elevated hepcidin occurs in multiple diseases associated with iron overload. Abnormal iron metabolism as a consequence of hepcidin dysregulation is an underlying factor resulting in pathophysiology of multiple diseases and several agents aimed at manipulating this pathway have been designed, with some already in clinical trials. In this chapter, we present an overview of and rationale for exploring the development of hepcidin agonists and antagonists in various clinical scenarios.

摘要

铁调素是铁代谢调节的核心。它在细胞水平上的作用包括与主要的铁输出蛋白铁转运蛋白结合,导致其内化和降解,从而使铁在表达铁转运蛋白的细胞内蓄积。铁调素异常增加会导致全身性缺铁和/或铁限制的红细胞生成。此外,在多种与铁过载相关的疾病中,铁调素升高不足。铁调素失调导致的铁代谢异常是多种疾病病理生理学的潜在因素,并且已经设计了一些旨在操纵该途径的药物,其中一些已经进入临床试验阶段。在本章中,我们概述了在各种临床情况下探索铁调素激动剂和拮抗剂的开发及其原理。

相似文献

1
Hepcidin-ferroportin axis in health and disease.
Vitam Horm. 2019;110:17-45. doi: 10.1016/bs.vh.2019.01.002. Epub 2019 Feb 8.
2
Hepcidin and its multiple partners: Complex regulation of iron metabolism in health and disease.
Vitam Horm. 2023;123:249-284. doi: 10.1016/bs.vh.2023.03.001. Epub 2023 Mar 30.
3
Regulators of hepcidin expression.
Vitam Horm. 2019;110:101-129. doi: 10.1016/bs.vh.2019.01.005. Epub 2019 Feb 2.
4
Modulation of hepcidin to treat iron deregulation: potential clinical applications.
Expert Rev Hematol. 2016;9(2):169-86. doi: 10.1586/17474086.2016.1124757. Epub 2015 Dec 15.
5
The dynamics of hepcidin-ferroportin internalization and consequences of a novel ferroportin disease mutation.
Am J Hematol. 2017 Oct;92(10):1052-1061. doi: 10.1002/ajh.24844. Epub 2017 Jul 29.
6
Hepcidin: Homeostasis and Diseases Related to Iron Metabolism.
Acta Haematol. 2017;137(4):220-236. doi: 10.1159/000471838. Epub 2017 May 18.
7
Current status of iron metabolism: Clinical and therapeutic implications.
Med Clin (Barc). 2017 Mar 3;148(5):218-224. doi: 10.1016/j.medcli.2016.10.047. Epub 2017 Jan 7.
8
Iron and hepcidin: a story of recycling and balance.
Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. doi: 10.1182/asheducation-2013.1.1.
9
Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis.
Int J Mol Sci. 2021 Jun 17;22(12):6493. doi: 10.3390/ijms22126493.
10
Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis.
Crit Rev Oncol Hematol. 2015 Jul;95(1):12-25. doi: 10.1016/j.critrevonc.2015.02.006. Epub 2015 Feb 18.

引用本文的文献

1
Multifaceted Marine Peptides and Their Therapeutic Potential.
Mar Drugs. 2025 Jul 15;23(7):288. doi: 10.3390/md23070288.
2
Endogenous hepcidin plays an essential role in Rv1876 antigen-induced antimicrobial activity in macrophages.
Emerg Microbes Infect. 2025 Dec;14(1):2539192. doi: 10.1080/22221751.2025.2539192. Epub 2025 Aug 6.
8
Lactoferrin-A Regulator of Iron Homeostasis and Its Implications in Cancer.
Molecules. 2025 Mar 28;30(7):1507. doi: 10.3390/molecules30071507.
9
Impact of inflammatory status on intestinal iron absorption in older hospitalized patients.
Eur J Clin Nutr. 2025 Mar 27. doi: 10.1038/s41430-025-01604-2.

本文引用的文献

1
Dysregulated iron metabolism in polycythemia vera: etiology and consequences.
Leukemia. 2018 Oct;32(10):2105-2116. doi: 10.1038/s41375-018-0207-9. Epub 2018 Jul 24.
2
Hepcidin Protects against Lethal Escherichia coli Sepsis in Mice Inoculated with Isolates from Septic Patients.
Infect Immun. 2018 Jun 21;86(7). doi: 10.1128/IAI.00253-18. Print 2018 Jul.
3
Hepcidin agonists as therapeutic tools.
Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.
4
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23.
5
Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor.
J Exp Med. 2018 Feb 5;215(2):661-679. doi: 10.1084/jem.20170396. Epub 2017 Dec 27.
6
Iron and infection.
Int J Hematol. 2018 Jan;107(1):7-15. doi: 10.1007/s12185-017-2366-2. Epub 2017 Nov 16.
7
Myeloproliferative Neoplasms.
N Engl J Med. 2017 Aug 31;377(9):895-6. doi: 10.1056/NEJMc1708485.
8
Iron- and Hepcidin-Independent Downregulation of the Iron Exporter Ferroportin in Macrophages during Infection.
Front Immunol. 2017 May 1;8:498. doi: 10.3389/fimmu.2017.00498. eCollection 2017.
9
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.
Blood. 2017 Jul 20;130(3):245-257. doi: 10.1182/blood-2017-03-772715. Epub 2017 May 2.
10
Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia.
JCI Insight. 2017 Mar 23;2(6):e92002. doi: 10.1172/jci.insight.92002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验